SCHEMBL3591375

SCHEMBL3591375

COC1CCN(C2Cc3cc(N)ccc3NC2=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
CRBN Q96SW2 5/20 0.37
IKZF2 Q9UKS7 1/20 0.37
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
APEX1 P27695 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DDB1 Q16531 3/20 0.34
ROCK2 O75116 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
IKZF3 Q9UKT9 2/20 0.33
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595503 0.91 CA9 (0.39) DRD2DRD4CRBNIKZF2ALOX15
SCHEMBL3591371 0.86 DRD2 (0.40) DRD2DRD4IKZF2ALOX15HSD17B10
SCHEMBL3604336 0.84 DRD2 (0.42) DRD2DRD4CRBNALOX15HSD17B10
SCHEMBL13545486 0.84 CRBN (0.38) DRD2DRD4CRBNIKZF2ALOX15
SCHEMBL3596528 0.84 DRD2 (0.46) DRD2DRD4CRBNKMT2AAPEX1
SCHEMBL3594463 0.83 DRD2 (0.45) DRD2DRD4CRBNKMT2AMEN1
SCHEMBL3580791 0.82 TSHR (0.46) DRD2DRD4CRBNKMT2AMEN1
SCHEMBL4457515 0.81 DRD2 (0.44) DRD2DRD4CRBNKMT2ADDB1
SCHEMBL3602300 0.81 DRD2 (0.44) DRD2DRD4CRBNHSD17B10KMT2A
SCHEMBL3604444 0.81 CRBN (0.41) DRD2DRD4CRBNKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 DRD2 530/4885DRD4 795/4885CRBN 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.